Wall Street brokerages expect that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will report earnings of ($0.17) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.19). Pieris Pharmaceuticals posted earnings per share of $0.17 during the same quarter last year, which would suggest a negative year over year growth rate of 200%. The company is expected to issue its next quarterly earnings report on Friday, March 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.44). For the next year, analysts expect that the firm will post earnings of ($0.77) per share, with EPS estimates ranging from ($0.95) to ($0.59). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The business had revenue of $8.35 million during the quarter, compared to analysts’ expectations of $6.16 million.
PIRS has been the subject of several analyst reports. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. HC Wainwright set a $12.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $10.00.
PIRS opened at $3.56 on Friday. Pieris Pharmaceuticals has a 1 year low of $3.24 and a 1 year high of $9.75. The firm has a market capitalization of $236.67 million, a P/E ratio of -8.90 and a beta of 1.94.
In other news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The stock was purchased at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.07% of the company’s stock.
A number of large investors have recently bought and sold shares of PIRS. Aquilo Capital Management LLC acquired a new position in Pieris Pharmaceuticals during the second quarter worth $10,013,000. BlackRock Inc. raised its position in Pieris Pharmaceuticals by 49.1% during the second quarter. BlackRock Inc. now owns 2,685,490 shares of the biotechnology company’s stock worth $13,616,000 after acquiring an additional 884,348 shares during the period. Prosight Management LP raised its position in Pieris Pharmaceuticals by 141.2% during the second quarter. Prosight Management LP now owns 1,360,000 shares of the biotechnology company’s stock worth $6,895,000 after acquiring an additional 796,237 shares during the period. Acadian Asset Management LLC raised its position in Pieris Pharmaceuticals by 45.5% during the second quarter. Acadian Asset Management LLC now owns 2,124,873 shares of the biotechnology company’s stock worth $10,773,000 after acquiring an additional 664,032 shares during the period. Finally, American Century Companies Inc. raised its position in Pieris Pharmaceuticals by 1,182.4% during the second quarter. American Century Companies Inc. now owns 467,779 shares of the biotechnology company’s stock worth $2,372,000 after acquiring an additional 431,302 shares during the period. Institutional investors own 65.26% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Recommended Story: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.